RxDoctor Payments Data

John Ohara, MD

Cardiovascular Disease · Paoli, PANPI 1548238173

Payments from drug & device makers

$557in general payments, 2019–2025

Across 23 payments — averaging $24.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$121
  • Boston Scientific$82
  • Amgen$64
  • E.r. Squibb & Sons, L.L.C.$60
  • Novartis$57
  • Merck$36
  • plus $137 from 6 others

What the payments were for

  • Food & beverage$557100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$557 in reported general payments places this provider in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$294,827
Medicare patients
1,247
Services billed
4,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban386$516,176
XareltoRivaroxaban143$172,679
Repatha SureclickEvolocumab101$136,949
EntrestoSacubitril/Valsartan62$92,201
JardianceEmpagliflozin36$55,334
Praluent PenAlirocumab47$46,680
Metoprolol Succinate828$16,455
Ezetimibe400$11,875
Atorvastatin Calcium734$10,283
Rosuvastatin Calcium488$6,299
Dabigatran EtexilateDabigatran Etexilate Mesylate14$5,749
Flecainide Acetate92$5,732
Losartan Potassium190$2,933
Ranolazine ErRanolazine12$2,880
Lisinopril271$2,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$516,176386 claims
Johnson & JohnsonXarelto$17$172,679143 claims
NovartisEntresto$57$92,20162 claims
Boehringer IngelheimJardiance$19$55,33436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →